Pharmaceutical composition for treating alcohol dependency

Abstract

Pharmaceutical composition for treating alcohol dependence in humans comprising two active ingredients: a compound having an antagonistic action on the 5-HT2 serotoninergic receptors selected as being cyproheptadine; and a compound having an antagonistic action on the alpha1-noradrenergic receptors selected from prazosin, alfuzosin, terazosin and tamsulosin.

1 . A pharmaceutical composition for treating alcohol dependence in humans comprising two active ingredients:
 a compound having an antagonistic action on the 5-HT2 serotoninergic receptors selected as being cyproheptadine; and   a compound having an antagonistic action on the alpha1-noradrenergic receptors selected from alfuzosin, terazosin and tamsulosin.   
     
     
         2 . (canceled) 
     
     
         3 . The pharmaceutical composition as claimed in  claim 1 , characterized in that it comprises:
 from 0.04 to 20 mg of cyproheptadine; and   from 0.075 to 10 mg of alfuzosin, from 0.01 to 5 mg of terazosin or from 0.004 to 0.4 mg of tamsulosin.   
     
     
         4 . The pharmaceutical composition as claimed in  claim 1  for administration 1 to 4 times daily to an alcohol-dependent patient. 
     
     
         5 . The pharmaceutical composition as claimed in  claim 1  for daily administration 1 to 7 days per week to an alcohol-dependent patient. 
     
     
         6 . A pharmaceutical product containing:
 a compound having an antagonistic action on the 5-HT2 serotoninergic receptors selected as being cyproheptadine; and   a compound having an antagonistic action on the alpha1-noradrenergic receptors selected from alfuzosin, terazosin and tamsulosin;   as a combination product for simultaneous, separate or spread over time administration for treating alcohol dependence in humans.   
     
     
         7 . A method for treating for treating alcohol dependence in humans comprising administering to a patient in need thereof a pharmaceutical composition comprising only two active ingredients, a first of the active ingredients is a compound having an antagonistic action on the 5-HT2 serotoninergic receptors selected as being cyproheptadine; and a second of the active ingredients is a compound having an antagonistic action on the alpha1-noradrenergic receptors selected from alfuzosin, terazosin and tamsulosin. 
     
     
         8 . The method of claim of  claim 7  wherein the composition comprises:
 from 0.04 to 20 mg of cyproheptadine; and 
 from 0.075 to 10 mg of alfuzosin, from 0.01 to 5 mg of terazosin or from 0.004 to 0.4 mg of tamsulosin. 
 
     
     
         9 . The method of  claim 7  wherein the composition is administered 1 to 4 times daily to the patient. 
     
     
         10 . The method of  claim 7  wherein the composition is administered daily 1 to 7 days per week to the patient. 
     
     
         11 . The method of  claim 7  wherein the two active ingredients are administered in a single dose. 
     
     
         12 . The method of  claim 7  wherein the two active ingredients are administered separately.